Adicet Bio (ACET) Income from Continuing Operations (2017 - 2026)
Adicet Bio (ACET) posted quarterly Income from Continuing Operations of 20244000.0 for Q1 2026, up 28.25% year-over-year from 15784993.81 in Q1 2025, and down 44108.7% quarter-over-quarter from 46000.0 in Q4 2025.
Adicet Bio (ACET) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Adicet Bio's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 20244000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 28.25% year-over-year to 20244000.0; the TTM figure through Mar 2026 stood at 47086000.0 (down 254.8% YoY), while the FY2025 annual figure was 86000.0, up 437.5% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 20244000.0, down from 46000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 88411000.0 in Q4 2024, with the low at 49885000.0 in Q3 2023.
- The 5-year median for Income from Continuing Operations is 22538000.0 (2022), against an average of 13308600.0.
- Peak annual rise in Income from Continuing Operations reached 121.66% in 2022, while the deepest fall reached 199863.64% in 2022.
- Adicet Bio's Income from Continuing Operations stood at 29875000.0 in 2022, then sank by 66.98% to 49885000.0 in 2023, then soared by 277.23% to 88411000.0 in 2024, then sank by 99.95% to 46000.0 in 2025, then sank by 44108.7% to 20244000.0 in 2026.
- Business Quant data shows ACET's Income from Continuing Operations at 20244000.0 in Q1 2026, 46000.0 in Q4 2025, and 26856000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Adicet Bio | 98.21 Mn | -19.98 Mn | - | -21.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.36 Mn |
| Mar 31, 2026 | -20.24 Mn |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | -26.86 Mn |
| Jun 30, 2025 | -32,000.00 |
| Mar 31, 2025 | -28.21 Mn |
| Dec 31, 2024 | 88.41 Mn |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | -29.90 Mn |
| Sep 30, 2023 | -49.89 Mn |
| Jun 30, 2023 | -32.40 Mn |
| Mar 31, 2023 | -30.88 Mn |
| Dec 31, 2022 | -29.88 Mn |
| Sep 30, 2022 | -22.00 Mn |
| Jun 30, 2022 | -22.54 Mn |
| Mar 31, 2022 | 4.62 Mn |
| Dec 31, 2021 | -15.81 Mn |
| Sep 30, 2021 | -11,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Mar 31, 2021 | -21.32 Mn |